NO20065380L - Anvendelse av R-(+)-2-(3-diisopropylamino-l-fenylpropyl)-4-hydroksymetyl-fenylisosmorsyrehydrogenfumarat for fremstilling av et medikament for behandling av urininkontinens og andre spasmogeniske sykdommer. - Google Patents

Anvendelse av R-(+)-2-(3-diisopropylamino-l-fenylpropyl)-4-hydroksymetyl-fenylisosmorsyrehydrogenfumarat for fremstilling av et medikament for behandling av urininkontinens og andre spasmogeniske sykdommer.

Info

Publication number
NO20065380L
NO20065380L NO20065380A NO20065380A NO20065380L NO 20065380 L NO20065380 L NO 20065380L NO 20065380 A NO20065380 A NO 20065380A NO 20065380 A NO20065380 A NO 20065380A NO 20065380 L NO20065380 L NO 20065380L
Authority
NO
Norway
Prior art keywords
diisopropylamino
phenylpropyl
spasmogenic
medicament
diseases
Prior art date
Application number
NO20065380A
Other languages
English (en)
Other versions
NO332637B1 (no
Inventor
Claus Meese
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7929277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065380(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20065380L publication Critical patent/NO20065380L/no
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of NO332637B1 publication Critical patent/NO332637B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C219/28—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Luminescent Compositions (AREA)

Abstract

Anvendelse av R-(+)-2-(3 -diisopropylamino-l-fenylpropyl)-4-hydroksymetyl-fenylisosmørsyre- hydrogenfimiarat eller den krystallinske form av R-(+)-2-(3-diisopropylamino-l-fenylpropyl)-4- hydroksymetyl-fenylisosmørsyrehydrogenfimiarat for fremstilling av et medikament for behandling av urininkontinens og andre spasmogeniske sykdommer.
NO20065380A 1999-11-16 2006-11-22 Anvendelse av R-(+)-2-(3-diisopropylamino-1-fenylpropyl)-4-hydroksymetyl-fenylisosmørsyreester- hydrogenfumarat for fremstilling av et medikament for behandling av urininkontinens og andre spasmogeniske sykdommer og farmasøytisk formulering derav NO332637B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19955190A DE19955190A1 (de) 1999-11-16 1999-11-16 Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen
PCT/EP2000/011309 WO2001035957A1 (de) 1999-11-16 2000-11-15 Stabile salze neuartiger derivate von 3,3-diphenylpropylaminen

Publications (2)

Publication Number Publication Date
NO20065380L true NO20065380L (no) 2002-05-15
NO332637B1 NO332637B1 (no) 2012-11-26

Family

ID=7929277

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20022314A NO323920B1 (no) 1999-11-16 2002-05-15 Stabile forbindelser av nye derivater av 3,3-difenylpropylaminer, fremgangsmåte for fremstilling derav og nye mellomprodukter
NO20065380A NO332637B1 (no) 1999-11-16 2006-11-22 Anvendelse av R-(+)-2-(3-diisopropylamino-1-fenylpropyl)-4-hydroksymetyl-fenylisosmørsyreester- hydrogenfumarat for fremstilling av et medikament for behandling av urininkontinens og andre spasmogeniske sykdommer og farmasøytisk formulering derav

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20022314A NO323920B1 (no) 1999-11-16 2002-05-15 Stabile forbindelser av nye derivater av 3,3-difenylpropylaminer, fremgangsmåte for fremstilling derav og nye mellomprodukter

Country Status (30)

Country Link
US (1) US6858650B1 (no)
EP (3) EP1230209B3 (no)
JP (6) JP4083431B2 (no)
KR (2) KR100563149B1 (no)
CN (1) CN1215045C (no)
AT (3) ATE337293T1 (no)
AU (1) AU778132B2 (no)
BR (1) BRPI0015610C1 (no)
CA (1) CA2389749C (no)
CY (2) CY1106204T1 (no)
CZ (2) CZ302497B6 (no)
DE (5) DE29923134U1 (no)
DK (3) DK1481964T3 (no)
EA (1) EA005588B1 (no)
ES (3) ES2236032T7 (no)
GE (1) GEP20084430B (no)
HK (3) HK1045148B (no)
HU (2) HU228197B1 (no)
IL (2) IL149567A0 (no)
IS (2) IS2124B (no)
MX (1) MXPA02004603A (no)
NO (2) NO323920B1 (no)
NZ (1) NZ519230A (no)
PL (1) PL201422B1 (no)
PT (3) PT1481964E (no)
SI (3) SI1481964T1 (no)
SK (3) SK288185B6 (no)
UA (2) UA73324C2 (no)
WO (1) WO2001035957A1 (no)
ZA (1) ZA200203315B (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE29923134U1 (de) * 1999-11-16 2000-06-29 Sanol Arznei Schwarz Gmbh Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen
DE10028443C1 (de) * 2000-06-14 2002-05-29 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen
DE10315878B4 (de) * 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
WO2005012227A2 (en) * 2003-08-05 2005-02-10 Ranbaxy Laboratories Limited Process for preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, a metabolite of tolterodine
ES2235648B1 (es) * 2003-12-22 2006-11-01 Ragactives, S.L. Procedimiento para la obtencion de tolterodina.
US8034823B2 (en) 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
KR100647068B1 (ko) 2005-09-15 2006-11-23 하나제약 주식회사 라세믹ｎ,ｎ-디이소프로필-3-(2-히드록시-5-메틸페닐)-3-페닐프로판아민의 제조방법
BRPI0712037A2 (pt) * 2006-05-24 2011-12-20 Pfizer Ltd processo para a produção de derivados benzopiran-2-ol
EP1862449A1 (en) * 2006-05-31 2007-12-05 Schwarz Pharma Ltd. A shortened synthesis of substituted hydroxymethyl phenols
AU2007267371B2 (en) * 2006-05-31 2012-09-20 Schwarz Pharma Ltd. New synthesis of substituted hydroxymethyl phenols
IES20060424A2 (en) 2006-06-08 2007-10-31 Schwarz Pharma Ltd Accelerated synthesis of (3-Diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol and its phenolic monoesters
US7807715B2 (en) 2006-06-09 2010-10-05 Ucb Pharma Gmbh Pharmaceutical compositions comprising fesoterodine
US7985873B2 (en) 2006-06-09 2011-07-26 Ucb Pharma Gmbh Synthesis of phenolic esters of hydroxymethyl phenols
AU2007255408B2 (en) * 2006-06-09 2013-03-14 Ucb Pharma Gmbh Stabilized pharmaceutical compositions comprising fesoterodine
CN101466695B (zh) 2006-06-12 2012-06-27 施瓦茨制药有限公司 新手性中间体、其制备方法及其在托特罗定、非索罗定或其活性代谢物制备中的用途
IES20060435A2 (en) * 2006-06-12 2007-12-12 Schwarz Pharma Ltd Shortened synthesis using paraformaldehyde or trioxane
WO2009037569A2 (en) * 2007-09-21 2009-03-26 Actavis Group Ptc Ehf An improved process for the preparation of fesoterodine
WO2009044278A1 (en) * 2007-10-01 2009-04-09 Actavis Group Ptc Ehf Amorphous fesoterodine fumarate
US20110086103A1 (en) * 2008-04-04 2011-04-14 Actavis Group Ptc Ehf Novel mandelate salt of fesoterodine
WO2010010464A2 (en) * 2008-07-21 2010-01-28 Actavis Group Ptc Ehf Fesoterodine substantially free of dehydroxy impurity
IT1392082B1 (it) * 2008-12-10 2012-02-09 Chemi Spa Nuove forme solide della fesoterodina fumarato
PL2416761T3 (pl) 2009-05-11 2015-07-31 Ratiopharm Gmbh Desfezoterodyna w postaci soli kwasu winowego
IT1394217B1 (it) 2009-05-15 2012-06-01 Chemi Spa Metodo di preparazione di fesoterodina e/o fesoterodina fumarato.
IT1394219B1 (it) * 2009-05-15 2012-06-01 Chemi Spa Metodo di preparazione di fesoterodina fumarato di elevata purezza.
KR20120053027A (ko) 2009-09-03 2012-05-24 테바 기오기스제르갸르 자르트쾨렌 뮈쾨되 레스즈베니타르사사그 페소테로딘 푸마레이트 및 페소테로딘 염기의 결정형
IT1396373B1 (it) * 2009-10-29 2012-11-19 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina.
EP2316432A1 (de) 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
US20110124903A1 (en) * 2009-11-20 2011-05-26 Actavis Group Ptc Ehf Solid state forms of fesoterodine intermediates
IT1397521B1 (it) * 2009-12-21 2013-01-16 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina con un basso contenuto di impurezze.
IT1397920B1 (it) * 2010-02-08 2013-02-04 Dipharma Francis Srl Forma cristallina di fesoterodina fumarato e procedimento per la sua preparazione
US20130172411A1 (en) 2010-03-22 2013-07-04 Cadila Healthcare Limited Stable pharmaceutical compositions comprising fesoterodine
JP5812500B2 (ja) 2010-04-30 2015-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 新規なβ３アドレナリン作動性受容体アゴニスト
WO2011141932A2 (en) 2010-05-11 2011-11-17 Intas Pharmaceuticals Limited Process for preparation of phenolic monoesters of hydroxymethyl phenols
WO2011145019A1 (en) * 2010-05-17 2011-11-24 Orchid Chemicals And Pharmaceuticals Limited Improved process for diphenylpropylamine derivatives
IT1401451B1 (it) 2010-06-10 2013-07-26 Chemi Spa Nuovo processo di preparazione di 2-idrossi-4-fenil-3,4-diidro-2h-cromen-6-il-metanolo e (r)-2-[3-(diisopropilammino)-1-fenilpropil]-4-(idrossimetil)fenolo.
WO2011158257A1 (en) 2010-06-18 2011-12-22 Panacea Biotec Ltd Preparation process of fesoterodine and intermediates
US9012678B2 (en) * 2010-08-25 2015-04-21 Cadila Healthcare Limited Processes for the preparation of fesoterodine
IT1403094B1 (it) * 2010-12-09 2013-10-04 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina o un suo sale
WO2012098560A2 (en) * 2011-01-17 2012-07-26 Msn Laboratories Limited Process for the preparation of muscarinic receptor antagonist
TWI590821B (zh) 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
EP2508173A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Stabilized pharmaceutical composition comprising fesoterodine
EP2508175A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof
JP6234999B2 (ja) 2012-05-04 2017-11-22 クリスタル ファルマ、エセ、ア、ウＣｒｙｓｔａｌ Ｐｈａｒｍａ，Ｓ．Ａ．Ｕ． 光学的に活性な３，３−ジフェニルプロピルアミンを調製するための方法
ITMI20121232A1 (it) 2012-07-16 2014-01-17 Cambrex Profarmaco Milano Srl Procedimento per la preparazione di 2-(3-n,n-diisopropilamino-1-fenilpropil)-4-idrossimetil-fenolo e suoi derivati
TR201721437A2 (tr) 2017-12-25 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari
EP4237405A1 (en) * 2020-10-27 2023-09-06 Wella Germany GmbH 2-methoxymethyl-p-phenylenediamine in cosmetic grade quality

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA817863B (en) * 1980-11-14 1983-06-29 Lilly Co Eli (-)n-methyl-3-(2-methylphenoxy)-3-phenylpropylamnie,antidepressant
IL66831A0 (en) * 1981-10-05 1982-12-31 Kefalas As Indane derivatives
SE8800207D0 (sv) * 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
ATE140213T1 (de) * 1990-03-08 1996-07-15 Fujisawa Pharmaceutical Co N-monosubstituierte cyclopentenylamine, ein verfahren zu ihrer herstellung, und ihre verwendung als medikament
JPH0483431A (ja) * 1990-07-26 1992-03-17 Seiko Epson Corp 選択呼出受信機
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
SE9701144D0 (sv) * 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE29923134U1 (de) * 1999-11-16 2000-06-29 Sanol Arznei Schwarz Gmbh Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen

Also Published As

Publication number Publication date
KR100563149B1 (ko) 2006-03-21
UA73324C2 (uk) 2005-07-15
PL201422B1 (pl) 2009-04-30
WO2001035957A8 (de) 2001-06-21
DE50013365D1 (de) 2006-10-05
HUP0900587A3 (en) 2010-04-28
DE29923134U1 (de) 2000-06-29
SK287430B6 (sk) 2010-09-07
EP1690536B1 (de) 2008-05-14
MXPA02004603A (es) 2004-09-10
JP2010180243A (ja) 2010-08-19
EP1230209B1 (de) 2005-01-12
JP4083431B2 (ja) 2008-04-30
SI1481964T1 (sl) 2006-12-31
EP1481964B1 (de) 2006-08-23
IS8382A (is) 2006-03-29
ZA200203315B (en) 2003-09-23
CZ20021343A3 (cs) 2002-09-11
EP1690536A3 (de) 2006-08-23
SK288384B6 (sk) 2016-08-01
DE50015163D1 (de) 2008-06-26
JP2014111589A (ja) 2014-06-19
EP1690536A2 (de) 2006-08-16
ES2303708T3 (es) 2008-08-16
HU0900587D0 (en) 2009-11-30
HK1045148A1 (en) 2002-11-15
PT1230209E (pt) 2005-05-31
DK1690536T3 (da) 2008-09-01
PT1690536E (pt) 2008-07-14
CA2389749A1 (en) 2001-05-25
DK1481964T3 (da) 2006-11-27
SK288185B6 (sk) 2014-04-02
IS6351A (is) 2002-04-19
PL356766A1 (en) 2004-07-12
HK1067114A1 (en) 2005-04-01
JP2007137895A (ja) 2007-06-07
US6858650B1 (en) 2005-02-22
CA2389749C (en) 2009-03-31
KR100536095B1 (ko) 2005-12-12
DE50009239D1 (de) 2005-02-17
JP2010180242A (ja) 2010-08-19
IL149567A0 (en) 2002-11-10
DE19955190A1 (de) 2001-06-21
HK1045148B (zh) 2005-05-06
ES2270240T3 (es) 2007-04-01
NO323920B1 (no) 2007-07-23
ES2236032T7 (es) 2012-06-14
NO20022314D0 (no) 2002-05-15
ATE395056T1 (de) 2008-05-15
BR0015610A (pt) 2002-07-30
NO20022314L (no) 2002-05-15
HU228197B1 (en) 2013-01-28
UA77322C2 (en) 2006-11-15
EP1481964A1 (de) 2004-12-01
ATE286872T1 (de) 2005-01-15
CZ302497B6 (cs) 2011-06-15
IS2124B (is) 2006-07-14
EP1230209B3 (de) 2011-10-05
BRPI0015610C1 (pt) 2021-05-25
KR20020059744A (ko) 2002-07-13
JP2003514018A (ja) 2003-04-15
EP1230209A2 (de) 2002-08-14
CN1390194A (zh) 2003-01-08
NO332637B1 (no) 2012-11-26
DK1230209T3 (da) 2005-05-30
SI1230209T1 (en) 2005-06-30
BR0015610B8 (pt) 2017-10-31
EA005588B1 (ru) 2005-04-28
KR20050100711A (ko) 2005-10-19
AU778132B2 (en) 2004-11-18
CN1215045C (zh) 2005-08-17
AU2666701A (en) 2001-05-30
WO2001035957A1 (de) 2001-05-25
JP5290351B2 (ja) 2013-09-18
HK1095736A1 (en) 2007-05-18
CZ302967B6 (cs) 2012-01-25
HUP0204034A3 (en) 2004-12-28
JP2011148824A (ja) 2011-08-04
HU227608B1 (en) 2011-09-28
IL149567A (en) 2007-08-19
JP5650924B2 (ja) 2015-01-07
WO2001035957A3 (de) 2001-12-27
CY1110389T1 (el) 2015-04-29
SI1690536T1 (sl) 2008-08-31
CY1106204T1 (el) 2011-06-08
JP5717824B2 (ja) 2015-05-13
EA200200511A1 (ru) 2002-10-31
HUP0204034A2 (hu) 2003-03-28
JP5503393B2 (ja) 2014-05-28
IS2673B (is) 2010-09-15
PT1481964E (pt) 2006-12-29
SK6572002A3 (en) 2002-12-03
ES2236032T3 (es) 2005-07-16
BRPI0015610B1 (pt) 2016-04-19
GEP20084430B (no) 2008-07-25
ATE337293T1 (de) 2006-09-15
NZ519230A (en) 2004-11-26

Similar Documents

Publication Publication Date Title
NO20065380L (no) Anvendelse av R-(+)-2-(3-diisopropylamino-l-fenylpropyl)-4-hydroksymetyl-fenylisosmorsyrehydrogenfumarat for fremstilling av et medikament for behandling av urininkontinens og andre spasmogeniske sykdommer.
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
HK1048313B (zh) 喹寧環丙烯酰胺
PL367277A1 (en) Methods of making sustained release formulations of oxymorphone related applications
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
DE69933208D1 (de) Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt
EE05025B1 (et) Fumaarhappe derivaadid kasutamiseks transplantaadivastase reaktsiooni raviks
ATE311148T1 (de) Chirurgische vorrichtungen
NZ545506A (en) Therapeutic agents useful for treating pain
SE9803518D0 (sv) Novel compounds
EP1952809A3 (en) Formulations for the reduction of breast density with 4-Hydroxy Tamoxifen
HK1047707A1 (zh) (+)-曲馬朵、o-去甲曲馬朵或(+)-o-去甲曲馬朵、o-去甲-n-單-去甲-曲馬朵或(+)-o-去甲-n-單-去甲-曲馬朵治療尿失禁的用途
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
NO982989L (no) Anvendelse av inhibitorer av den cellulµre Na+/H+-utbytteren (NHE) for fremstilling av et medikament for respiratorstimulering
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
KR950701612A (ko) 포타슘 채널 오프너 및 요실금 치료제로서의 알콜(alcohols as potassium channel openers and in treatment of urinary inconitnence)
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
ATE447953T1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
GB9227123D0 (en) Method
NZ334571A (en) Pharmaceutical composition comprising 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy-acetic acid for treating diseases induced by respiratory syncytial virus
NO20032411L (no) Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens
SE0103325D0 (sv) Novel compounds
ATE207353T1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
SE9901530D0 (sv) Novel compounds

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: PFIZER INC., US

Owner name: UCB PHARMA GMBH, DE

CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO

MK1K Patent expired